Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

HFrEF - Heart Failure With Reduced Ejection Fraction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Infarction (MI) Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The history of acute myocardial infarction exceeds 3 months;
Symptoms and signs of heart failure have been stable for more than one month;
18 years old or more;
NYHA cardiac function classified as grade II~IV;
LVEF≤40%；
NT-proBNP≥450pg/ml；
All subjects or their guardians must sign the subject consent before entering the trial.

Exclusion criteria

Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
Mechanical complications of myocardial infarction;
Unable to obtain primary outcome data.

Treatment and study plan

Vericiguat Oral Tablet [Verquvo]

Drug

Vericiguat in addition to conventional treatment

Other names: Conventional treatment

Prescription Drugs

Drug

Conventional treatment only

Other names: Conventional treatment without vericiguat

Primary outcomes

LVEDVI=LVEDV/BSA

Time frame: From baseline to the end of 12-month treatment

Changes of left ventricular end-diastolic volume index (LVEDVI) compared with baseline after 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Panpan Hao, MD, PhD

CONTACT

[email protected]

86-18560086593

Sponsors and collaborators

Lead sponsor

Qilu Hospital of Shandong University

Other

Collaborators

Jinan Central Hospital
Qianfoshan Hospital

Registry information

Official study title

Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

Acronym: HFrEF

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Dec 4, 2024
Registry last updated: Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation